U.S. Therapeutic Plasma Exchange Market by Indication, Procedures & Patients - Forecasts to 2021

Description: U.S. Therapeutic Plasma Exchange Market by Indication (Neurological & Autoimmune Disorders), Procedures & Patients (Guillain Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura, Glomerulonephritis) - Forecasts to 2021

The U.S. therapeutic plasma exchange (TPE) market by indication is estimated to reach USD 260.0 million by 2021, growing at a CAGR of 11% to 12% during the forecast period (2016 to 2021). The rising incidences of blood disorders and chronic diseases; rapid increase in the aging population; and increasing adoption of therapeutic plasma exchange in rare neurological, hematology, and autoimmune disorders are key factors driving the therapeutic plasma exchange market in the U.S. In this report, the market is segmented by indication, number of patients, and total number of TPE procedures performed by indication.

Therapeutic plasma exchange removes plasma components from blood. A blood cell separator extracts the patient's plasma and returns red blood cells (RBCs) and platelets in plasma or a plasma-replacing fluid; for this purpose, 5% albumin is preferred to fresh frozen plasma (except for patients with thrombotic thrombocytopenic purpura) because it causes fewer reactions and transmits no infections. Therapeutic plasma exchange resembles dialysis but, in addition, can remove protein-bound toxic substances. A one-volume exchange removes about 66% of such components. Due to this factor, the awareness among physicians is growing, hence therapeutic plasma exchange is increasingly being adopted in the treatment of rare diseases such as Guillain-Barré syndrome, thrombotic thrombocytopenic purpura (TTP), Goodpasture syndrome, and Wegener's Granulomatosis. This trend is expected to continue in the coming years as well.

The U.S. therapeutic plasma exchange (TPE) market by indication is broadly segmented into neurological disorders, hematology disorders, renal disorders, autoimmune disorders, and metabolic disorders. In 2015, the neurological disorders segment accounted for the largest share of the U.S therapeutic plasma exchange market; this segment is also projected to grow at the highest CAGR during the forecast period. The growing prevalence of neurological diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and myasthenia gravis; and growing prevalence of multiple sclerosis in the U.S. are driving the growth in this market segment.

The major players in the U.S. TPE market are Haemonetics Corporation (U.S.), Fresenius Medical Care (Germany), Terumo BCT, Inc. (U.S.), Baxter International Inc. (U.S.), Asahi Kasei Medical Co., Ltd. (Japan), Kawasumi Laboratories Inc. (Japan), B. Braun Melsungen AG (Germany), and HemaCare Corporation (U.S.).

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater market share. Firms purchasing the report could use one or a combination of the below-mentioned four strategies (market penetration, product development/innovation, market diversification, and competitive assessment) for reaping greater market shares.

This report provides insights on the following pointers:

- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the therapeutic plasma exchange market. The report analyzes the therapeutic plasma exchange market by indication, total number of TPE procedures performed, and number of patients treated with TPE in the U.S.

- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and new product launches in the therapeutic plasma exchange market

- Market Diversification: Exhaustive information about new products, major product segments and indications, recent developments, and investments in the therapeutic plasma exchange market

Competitive Assessment: In-depth assessment of market shares, growth strategies, products, distribution
networks, manufacturing capabilities, and product portfolio and pricing analyses of the leading players in the therapeutic plasma exchange market.

Contents:

1 Introduction
  1.1 Objectives and Scope
  1.2 Research Methodology
  1.3 Market Estimation Methodology
  1.4 Primary Research Methodology
  1.5 Primary Respondent Profile

2 Key Insights

3 Therapeutic Plasma Exchange Market, By Indication
  3.1 Guillain-Barré Syndrome (GBS)
  3.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  3.3 Myasthenia Gravis (MG)
  3.4 Multiple Sclerosis (MS)
  3.5 Neuromyelitis Optica (NMO)
  3.6 Thrombotic Thrombocytopenic Purpura (TTP)
  3.7 Cryoglobulinemia
  3.8 Multiple Myeloma (MM)
  3.9 Waldenstrom Macroglobulinemia (WM)
  3.10 Hemolytic Uremic Syndrome (HUS)
  3.11 Anti-GBM Disease (Goodpasture's Syndrome)
  3.12 Wegener's Granulomatosis (Anca-Associated Rapidly Progressive Glomerulonephritis)
  3.13 Post-Renal Transplant Rejection
  3.14 Familial Hypercholesterolemia (Homozygous)
  3.15 Anca-Associated Vasculitis

4 Appendix
  4.4.1 Company Profiles
  4.4.1.1 Fresenius Se & Co. KGAA
  4.4.1.2 B. Braun Melsungen AG
  4.4.1.3 Baxter International Inc
  4.4.1.4 Asahi Kasei Medical Co., Ltd.
  4.4.1.5 Terumo BCT, Inc.
  4.4.1.6 Haemonetics Corporation
  4.4.1.7 Kawasumi Laboratories, Inc.
  4.4.1.8 Hemacare Corporation
  4.5 Knowledge Store: Subscription Portal

List of Tables (55 Tables)

Table 1 Data Model
Table 2 U.S.: Therapeutic Plasma Exchange Market Size, By Indication, 2014-2021 (USD Million)
Table 3 U.S.: Therapeutic Plasma Exchange Market- Patient Population and Number of Procedures
Table 4 U.S. Disease Statistics: Acute Inflammatory Demyelinating Polyneuropathy
Table 5 Treatment Guidelines & Protocols : Guillain-Barré Syndrome (GBS)
Table 6 Epidemiology : Guillain-Barré Syndrome (GBS)
Table 7 U.S. Disease Statistics: Chronic Inflammatory Demyelinating Polyneuropathy
Table 8 Treatment Guidelines & Protocols : Chronic Inflammatory Demyelinating Polyneuropathy
Table 9 Epidemiology : Chronic Inflammatory Demyelinating Polyneuropathy
Table 10 U.S. Disease Statistics: Myasthenia Gravis (MG)
Table 11 Treatment Guidelines & Protocols : Myasthenia Gravis (MG)
Table 12 Epidemiology : Myasthenia Gravis (MG)
Table 13 U.S. Disease Statistics: Multiple Sclerosis (MS)
Table 14 Treatment Guidelines & Protocols : Multiple Sclerosis (MS)
Table 15 Epidemiology : Multiple Sclerosis (MS)
Table 16 U.S. Disease Statistics: Neuromyelitis Optica (NMO)
Table 17 Treatment Guidelines & Protocols : Neuromyelitis Optica (NMO)
Table 18 Epidemiology : Neuromyelitis Optica (NMO)
Table 19 U.S. Disease Statistics: Thrombotic Thrombocytopenic Purpura (TTP)
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: U.S. Therapeutic Plasma Exchange Market by Indication, Procedures & Patients - Forecasts to 2021
Web Address: http://www.researchandmarkets.com/reports/3785830/
Office Code: SCBRFF96

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 5650</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td></td>
<td>USD 6650</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 8150</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World